10mM in DMSO for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 3 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Information
Benazepril HCl (CGS 14824A) is a novelangiotensin I converting enzymeinhibitor, used primarily in treatment of hypertension.
In vitro
In vivo
Benazepril hydrochloride (3 or 10 mg/kg/d, p.o. for 14 days) dose-dependently inhibits the increase in the blood pressure caused by continuous norepinephrine (NE) infusion in spontaneously hypertensive rats (SHR) and suppresses in seizures induced by a monoamine oxidase inhibitor, tranylcypromine in NE infused SHR. Benazepril hydrochloride (30 mg/kg p.o.) decreases the triglyceride and total cholesterol levels in normotensive rats. Benazepril hydrochloride (3 mg/kg s.c.) causes a significant decrease in aortic atherosclerosis without reducing hypercholesterolemia in cholesterol-fed rabbits. Benazepril hydrochloride (100 mg/kg p.o.) shows no effect on the urine volume and urinary excretion of electrolytes but decreases PSP excretion in normotensive rats. Benazepril hydrochloride (10 mg/kg p.o.) inhibits the increase in the excretion of urinary protein in DOCA/salt spontaneously hypertensive rats. Benazepril Hydrochloride administration corrects systemic hypertension and significantly reduces angiotensin II and aldosterone in cats with experimentally induced or spontaneously occurring chronic renal failure. Benazepril hydrochloride administration reduces serum creatinine and urinary protein concentration in cat with experimentally induced or spontaneously occurring chronic renal failure. Benazepril hydrochloride significantly decreases blood pressure, angiotensin II and aldosterone and, increases upon discontinuation of administration to the pre-administration levels in a canine remnant kidney model of chronic renal failure.
Cell Data
cell lines：
Concentrations：
Incubation Time：
Powder Purity:≥99%
| Isomere SMILES | CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCC3=CC=CC=C3N(C2=O)CC(=O)O.Cl |
|---|---|
| WGK Deutschland | 2 |
| RTECS | CX7065000 |
| Molekulargewicht | 460.95 |
| Reaxy-Rn | 13349075 |
| Reaxys-RN_link_address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=13349075&ln= |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →| Löslichkeit | Solubility (25°C) In vitro |
|---|---|
| Spezifische Drehung [α] | -134.0 to -140.0 deg(C=1, EtOH) |
| Schmelzpunkt (°C) | 183°C(lit.) |
| 1. Zheng Di-Wei, Pan Pei, Chen Ke-Wei, Fan Jin-Xuan, Li Chu-Xin, Cheng Han, Zhang Xian-Zheng. (2020) An orally delivered microbial cocktail for the removal of nitrogenous metabolic waste in animal models of kidney failure. Nature Biomedical Engineering, 4 (9): (853-862). [PMID:32632226] [10.1038/s41551-020-0582-1] |
| 2. Wang Yiran, Shi Jihua, Dai Dapeng, Cai Jianping, Wang Shuanghu, Hong Yun, Zhou Shan, Zhao Fangling, Zhou Quan, Geng Peiwu, Zhou Yunfang, Xu Xue, Luo Qingfeng. (2022) Evaluation of commonly used cardiovascular drugs in inhibiting vonoprazan metabolism in vitro and in vivo. Frontiers in Pharmacology, [PMID:36052128] [10.3389/fphar.2022.909168] |
| 3. Tan Lihua, Tu Yanbei, Wang Kai, Han Bing, Peng Hongquan, He Chengwei. (2020) Exploring protective effect of Glycine tabacina aqueous extract against nephrotic syndrome by network pharmacology and experimental verification. Chinese Medicine, 15 (1): (1-17). [PMID:32765640] [10.1186/s13020-020-00361-7] |
